Add to ORKGThe present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
A construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a nanoparticle; ...
vancomycin-resistant enterococci. from LY264826 active against Semisynthetic glycopeptide antibiotic...
The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to carboxylic acid esters of deglucoteicoplanin, i.e. of the aglyc...
The present invention is directed to a chemical process for preparing antibiotic L 17392 (deglucotei...
The aim of experiment is to synthesize a new teicoplanin pseudoaglycon derivative through a maleimid...
The present invention is directed to ester derivatives at the carboxylic function of the glycopeptid...
SummaryThe unique glycopeptide antibiotic A47934, produced by Streptomyces toyocaensis, possesses a ...
Glycopeptide antibiotics, vancomycin and teicoplanin, inhibit cell wall synthesis in Gram-positive b...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
A construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a nanoparticle; ...
vancomycin-resistant enterococci. from LY264826 active against Semisynthetic glycopeptide antibiotic...
The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to the essentially pure preparation of an antibiotic substance arb...
The present invention is directed to carboxylic acid esters of deglucoteicoplanin, i.e. of the aglyc...
The present invention is directed to a chemical process for preparing antibiotic L 17392 (deglucotei...
The aim of experiment is to synthesize a new teicoplanin pseudoaglycon derivative through a maleimid...
The present invention is directed to ester derivatives at the carboxylic function of the glycopeptid...
SummaryThe unique glycopeptide antibiotic A47934, produced by Streptomyces toyocaensis, possesses a ...
Glycopeptide antibiotics, vancomycin and teicoplanin, inhibit cell wall synthesis in Gram-positive b...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. ...
A construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a nanoparticle; ...
vancomycin-resistant enterococci. from LY264826 active against Semisynthetic glycopeptide antibiotic...